Puma Biotechnology Inc, the rise of an underdog? - November 2025Puma Biotechnology IncBATS:PBYIwithout_worriesFor years Puma Biotechnology (NASDAQ:PBYI) has lived quietly in the shadows, the biotech equivalent of a washed up boxer still training in a basement gym waiting for one last fight. But recently, something changed. The chart tells the story better than any press release ever could. After almost eight years inside a descending channel, price action has broken above the upper resistance boundary for the first time since 2015. The breakout coincides with two clear technical signals: 1. A sequence of higher lows since 2023, showing accumulation beneath long term resistance. 2. A confirmed higher high into late 2025, with bullish follow-through volume. The multi-year downtrend that defined this stock is now, quite possibly, over. Support and Resistance The blue zone between $3.00 and $5 has acted as a pivot level for nearly 5 years, first as support, then as resistance ever since the Bottoming candle print. The area highlighted by the blue circle is significant. The importance of this one candle would ellipse many, it is the candle that informs you the bottoming candle has now become support. Support on past resistance. From here on it is on to test the next levels of resistance: $12.50 $40.00 $90.00 Momentum & RSI The RSI (lower panel) has been quietly forming its own comeback arc. Since 2018, RSI has been locked within a long term descending channel, every rally capped by the same resistance zone. Now? It’s different. RSI support has formed above the old channel, that’s excellent. The story so far Puma spent most of the 2015–2023 period being punished by the market. Revenue stagnated, sentiment collapsed, and remaining investors now asking the trivia question: is the business still viable? Charts are agnostic. What matters isn’t the story, it’s the structure. And structurally has done something it hasn’t done in years, stopped falling. Should the structure hold above $3.00, then fantastic. Forecasts are shown by the black lines. It’s a big “if” but that’s where asymmetric opportunity lives. This is what happens when an ignored chart wakes up: quietly at first, then all at once. Conclusions Most of the market’s attention is glued to mega caps as the AI narrative continues to climb the wall of worry, meanwhile market participants ignore value like it doesn’t exist. But every so often, something buried deep in the biotech rubble starts twitching. Puma has been underwater for nearly a decade. Now it’s taken its first breath, whether it runs or sinks again depends entirely on that $3.00–$3.60 support zone continuing. If it holds, the next few quarters could surprise everyone who wrote it off. If it fails… well, gravity still works. Ww ============================== Disclaimer This isn’t financial advice, obviously. If you buy a biotech stock because a stranger on the internet drew lines on a chart, you deserve whatever plot twist comes next. Do your own research, manage your risk, and remember: hope isn’t a strategy it’s just bad risk management with better PR.